First patient dosed in phase III clinical trial of monalizumab + cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck,- Innate Pharma + AstraZeneca.
Read time: 1 mins
Last updated:26th Oct 2020
Published:24th Oct 2020
Innate Pharma SA announced that AstraZeneca has dosed the first patient in its Phase III clinical trial, INTERLINK-1, evaluating monalizumab in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who have been previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors (“IO-pretreated”) Monalizumab, Innate’s lead partnered asset, is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
Condition: Head & Neck Cancer